Background: Preoperative inflammatory indicators had been found to correlate with tumor prognosis, contributing to patient stratification and precise treatment. Objectives: The proportion of Platelet-lymphocytes ratio was associated with the progression of laryngeal cancer, however the results were not consistent. Therefore, we used a meta-analysis to evaluate the prediction of preoperative Platelet-lymphocytes ratio （PLR）for laryngeal cancer outcomes. Methods: We searched WOS, Ovid, Pubmed and The Cochrane library for articles on PLR and Overall Survival(OS) and Progression-free survival(PFS) of patients with laryngeal cancer, from January 1, 2000 to May 1, 2021. State 12.0 was used for conbination analysis. Fixed effects model and random effects model were used to calculated HR and 95%CI. Preferred reporting items that follow systematic review and meta-analysis (PRISMA) guidelines. Results: This meta-analysis eventually included 1,711 cases from 7 studies. The merge OS, HR=1.70, 95%CI 1.11-2.61; PFS, HR=1.34, 95%CI 0.47-3.81. Subgroup analysis included sample size, cut-off, treatment, variable and disease stage showed that a poor OS in patients with increased PLR. Conclusion: Higher PLR may be an adverse prognostic factor for laryngeal cancer. PLR could be obtained by regularly preoperative test, it could help surgeons to evaluate the prognosis of patients with laryngeal cancer. Key words: Laryngeal cancer; Platelet-lymphocytes ratio; Meta-analysis; System review.

Background: The use of immunotherapy to treat recurrent/metastatic squamous cell carcinoma of the head and neck has become a popular research topic in recent years, and many clinical trials have been carried out. Objectives: To systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Methods: We searched PubMed, Embase, Cochrane Library and other databases up to 1 November 2019 for publications reporting the use of PD-1/PD-L1 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Revman 5.0 was used for combination analysis, and the overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and adverse events were determined. Results: Five articles were included. Compared with other treatment methods, this meta-analysis showed that treatment with PD-1/PD-L1 inhibitors can significantly improve OS (P < 0.0001), but there was no significant improvement in PFS or ORR. The risk of anaemia and nausea was significantly reduced by treatment with PD-1/PD-L1 inhibitors. Conclusions and Significance: Treatment with PD-1/PD-L1 inhibitors alone can improve the overall survival rate for recurrent/metastatic squamous cell carcinoma of the head and neck but there is no obvious advantage in other aspects and adverse events.

Objectives: The expression of CD3, CD4, CD8, PD-1 and PD-L1 in mucosal malignant melanoma tumors was analyzed by immunohistochemical staining. The aim was to explore the characteristics of malignant melanoma in head and neck and its correlation with the expression of these factors, to further our understanding of the disease. Design:Retrospective clinical study. Setting: Otorhinolaryngology unit of a tertiary hospital. Participants: 36 patients underwent immunohistochemical staining. Main outcome measures: In total, 24 patients underwent immunohistochemical staining of CD4, CD8, PD-1, and PD-L1, and 12 patients underwent CD3 immunohistochemical staining. Results: There was no significant difference between the expression of CD3, CD4, or CD8 and the general clinical features of mucosal melanoma. However, (1) the high rate of expression of CD8 was significantly different in different lesion locations: 85.71% in the nasal cavity/sinus/nasal cavity and sinus, and 66.67% in the nasopharynx; (2) the expression of PD-L1 was statistically significantly correlated with the combined expression of CD4, CD8 and CD4/CD8 (r = 0.451, P < 0.05); (3) the median progression-free survival times of patients with high and low expression CD4 were 24 months and 4 months, respectively, and those of patients with high and low expression of CD8 were 24 months and 6 months, respectively. Conclusions: The correlation between the expression of CD8 and PD-L1 suggests the role of tumor infiltrating lymphocytes in anti-tumor immunity and their possible use as immunotherapy markers. In addition, the expression of CD4 and CD8 in tumor tissue may play a guiding role in the prognosis of patients.